Zepbound, which is already sold by Eli Lilly as the diabetes treatment Mounjaro, was shown to reduce patients’ weight by as much as one-fifth in drug trials.
Novo Nordisk, the Danish company behind two popular obesity medications, is reaping huge profits and is now responsible for most of Denmark’s economic growth.